<img alt="" src="https://secure.52enterprisingdetails.com/787780.png" style="display:none;">
Skip to content
    en

    TB or not TB - or DR-TB? Introducing a new EQA scheme for Mycobacterium tuberculosis drug resistance

    Aurevia, a Finnish independent EQA provider, has introduced a new EQA scheme for Mycobacterium tuberculosis, drug resistance (DR), by performing a pilot study named Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection in June 2022. 
    Fill in the form and download the poster
    posters_RIF

    Fill in the form and download the poster

    From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

    Please review our Privacy Policy.

    By clicking submit below, you consent to Aurevia storing and processing the information submitted above to provide you with the content or service requested.